GAMMAGARD Liquid
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- GAMMAGARD Liquid
- Generic name
- IMMUNE GLOBULIN INFUSION (HUMAN)
- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 9d42adca-0dd7-4df7-864d-5a7feee52130
- SPL ID
- 22fa0cdc-9566-4219-ba2b-2f2122370641
- Version
- 22
- Effective date
- 2025-12-10
- Source export date
- 2026-11-13
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:35:17
| Harmonized routes |
|---|
| INTRAVENOUS, SUBCUTANEOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125105 | derived:openfda.application_number |
| application number | BLA125105 | openfda.application_number | |
| brand name | GAMMAGARD Liquid | openfda.brand_name | |
| generic name | IMMUNE GLOBULIN INFUSION (HUMAN) | openfda.generic_name | |
| manufacturer name | Takeda Pharmaceuticals America, Inc. | openfda.manufacturer_name | |
| ndc | package | 0944-2700-10 | openfda.package_ndc |
| ndc | package | 0944-2700-02 | openfda.package_ndc |
| ndc | package | 0944-2700-03 | openfda.package_ndc |
| ndc | package | 0944-2700-07 | openfda.package_ndc |
| ndc | package | 0944-2700-06 | openfda.package_ndc |
| ndc | package | 0944-2700-04 | openfda.package_ndc |
| ndc | package | 0944-2700-09 | openfda.package_ndc |
| ndc | package | 0944-2700-12 | openfda.package_ndc |
| ndc | package | 0944-2700-11 | openfda.package_ndc |
| ndc | package | 0944-2700-05 | openfda.package_ndc |
| ndc | package | 0944-2700-08 | openfda.package_ndc |
| ndc | package | 0944-2700-13 | openfda.package_ndc |
| ndc | product | 0944-2700 | openfda.product_ndc |
| ndc11 | package | 00944270010 | derived:openfda.package_ndc |
| ndc11 | package | 00944270007 | derived:openfda.package_ndc |
| ndc11 | package | 00944270013 | derived:openfda.package_ndc |
| ndc11 | package | 00944270004 | derived:openfda.package_ndc |
| ndc11 | package | 00944270008 | derived:openfda.package_ndc |
| ndc11 | package | 00944270003 | derived:openfda.package_ndc |
| ndc11 | package | 00944270009 | derived:openfda.package_ndc |
| ndc11 | package | 00944270011 | derived:openfda.package_ndc |
| ndc11 | package | 00944270012 | derived:openfda.package_ndc |
| ndc11 | package | 00944270006 | derived:openfda.package_ndc |
| ndc11 | package | 00944270002 | derived:openfda.package_ndc |
| ndc11 | package | 00944270005 | derived:openfda.package_ndc |
| rxcui | 1809444 | openfda.rxcui | |
| rxcui | 1809438 | openfda.rxcui | |
| rxcui | 1809672 | openfda.rxcui | |
| rxcui | 1809670 | openfda.rxcui | |
| rxcui | 1809671 | openfda.rxcui | |
| rxcui | 1809668 | openfda.rxcui | |
| rxcui | 1809434 | openfda.rxcui | |
| rxcui | 1809421 | openfda.rxcui | |
| rxcui | 1809667 | openfda.rxcui | |
| rxcui | 1809665 | openfda.rxcui |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE ▪ Thrombosis may occur with immune globulin products, including GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors [see Warnings and Precautions (5.4) , Patient Counseling Information (17) ] . ▪ Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. GAMMAGARD LIQUID does not contain sucrose. [see Warnings and Precautions (5.2) ▪ For patients at risk of thrombosis, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity [see Dosage and Administration (2.3) and Warnings and Precautions (5.4) ] . WARNING: THROMBOSIS , RENAL DYSFUNCTION and ACUTE RENAL FAILURE See full prescribing information for complete boxed warning . ▪ Thrombosis may occur with immune globulin products, including GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. ( 5.4 ) ▪ Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products including GAMMAGARD LIQUID. Renal dysfunction and acute failure occur more commonly with IGIV products containing sucrose. GAMMAGARD LIQUID does not contain sucrose. ( 5.2 ) ▪ For patients at risk of thrombosis, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. ( 5.4 )
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS ▪ IgA deficient patients with antibodies to IgA are at greater risk of developing severe hypersensitivity and anaphylactic reaction. ( 5.1 ) ▪ Monitor renal function, including blood urea nitrogen, serum creatinine, and urine output in patients at risk of acute renal failure. ( 5.2 ) ▪ Hyperproteinemia, increased serum viscosity and hyponatremia may occur. ( 5.3 ) ▪ Thrombosis may occur. Monitor for signs and symptoms of thrombosis and assess blood viscosity for those at risk for hyperviscosity. ( 5.4 ) ▪ Aseptic Meningitis Syndrome (AMS) may occur. ( 5.5 ) ▪ Hemolytic anemia can develop. Monitor for clinical signs and symptoms of hemolysis and hemolytic anemia. ( 5.6 ) ▪ Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury, TRALI). ( 5.7 ) ▪ GAMMAGARD LIQUID is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease agent ( 5.8 ) 5.1 Hypersensitivity Severe hypersensitivity reactions may occur, even in patients who had tolerated previous treatment with human normal immune globulin. In case of hypersensitivity, discontinue GAMMAGARD LIQUID infusion immediately and institute appropriate treatment. GAMMAGARD LIQUID contains trace amount of IgA (average concentration of 37 μg/mL). Patients with antibodies to IgA have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. GAMMAGARD LIQUID is contraindicated in patients with antibodies against IgA and a history of hypersensitivity reaction [see Contraindications (4.1) ] . 5.2 Renal Dysfunction/Failure Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur upon use of IGIV treatment, especially those containing sucrose 3 . Acute renal dysfunction/failure has been reported in association with infusions of GAMMAGARD LIQUID. Assure that patients are not volume depleted prior to the initiation of infusion of GAMMAGARD LIQUID. In patients who are at risk of developing renal dysfunction because of pre-existing renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs, etc.), administer GAMMAGARD LIQUID intravenously at the minimum rate of infusion practicable (not exceeding 3.3 mg IgG/kg/min (<2 mL/kg/hr) [see Dosage and Administration (2.5) ] . Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk for developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of GAMMAGARD LIQUID and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation of GAMMAGARD LIQUID [see Dosage and Administration (2.5) ] . 5.3 Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia Hyperproteinemia, increased serum viscosity and hyponatremia may occur in patients receiving GAMMAGARD LIQUID. It is critical to distinguish true hyponatremia from pseudohyponatremia that is temporally or causally related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap. Treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity, and a predisposition to thromboembolic events. 4 5.4 Thrombosis Thrombosis may occur following treatment with immune globulin products, including GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity [see Boxed Warning , Dosage and Administration (2.5) , Patient Counseling Information (17) ] . 5.5 Aseptic Meningitis Syndrome (AMS) AMS may occur with immune globulin treatment, including GAMMAGARD LIQUID, administered intravenously or subcutaneously. AMS may occur more frequently in female patients. Discontinuation of immune globulin treatment has resulted in remission of AMS within several days without sequelae. The syndrome usually begins within several hours to two days following immune globulin treatment. AMS is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea and vomiting [see Patient Counseling Information (17) ] . Cerebrospinal fluid (CSF) studies frequently reveal pleocytosis up to several thousand cells per mm 3 , predominantly from the granulocytic series, and elevated protein levels up to several hundred milligram/dL, but negative culture results. Conduct a thorough neurological examination on patients exhibiting such symptoms and signs, including CSF studies, to rule out other causes of meningitis. 5.6 Hemolysis GAMMAGARD LIQUID, contains blood group antibodies that may act as hemolysins and induce in vivo coating of red blood cells (RBC) with immune globulin. This may cause a positive direct antiglobulin test [DAT (Coomb's test)]. 5,6 Delayed hemolytic anemia can develop subsequent to GAMMAGARD LIQUID therapy due to enhanced RBC sequestration; acute hemolysis, consistent with intravascular hemolysis, has been reported [see Adverse Reactions (6) ] . 5-8 The following risk factors may be related to the development of hemolysis: high doses (e.g., ≥2 grams/kg, single administration or divided over several days) and non-O blood group. 5 Underlying inflammatory state in an individual patient may increase the risk of hemolysis, 5 but its role is uncertain. 8,9 Monitor patients for clinical signs and symptoms of hemolysis particularly patients with risk factors noted above. Consider appropriate laboratory testing in higher risk patients, including measurement of hemoglobin or hematocrit prior to infusion and within approximately 36 to 96 hours post infusion. If clinical signs and symptoms of hemolysis or a significant drop in hemoglobin or hematocrit have been observed, perform additional confirmatory laboratory testing. If transfusion is indicated for patients who develop hemolysis with clinically compromising anemia after receiving IGIV, perform adequate cross-matching to avoid exacerbating on-going hemolysis [see Warnings and Precautions (5.9) ] . 5.7 Transfusion-Related Acute Lung Injury (TRALI) Non-cardiogenic pulmonary edema (TRALI) has been reported in patients following treatment with IGIV products, including GAMMAGARD LIQUID. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Symptoms typically occur within 1 to 6 hours after treatment. Monitor patients for pulmonary adverse reactions [see Patient Counseling Information (17) ] . If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support. 5.8 Transmissible Infectious Agents Because GAMMAGARD LIQUID is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease agent. This also applies to unknown or emerging viruses and other pathogens. No confirmed cases of viral transmission or vCJD have been associated with GAMMAGARD LIQUID. All infections thought by a physician to possibly have been transmitted by this product should be reported by the physician or other healthcare provider to Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) (in the U.S.). 5.9 Monitoring: Laboratory Tests ▪ Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of GAMMAGARD LIQUID and at appropriate intervals thereafter. ▪ Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies, because of the potentially increased risk of thrombosis. 3,4 ▪ If signs and/or symptoms of hemolysis are present after an infusion of GAMMAGARD LIQUID, perform appropriate laboratory testing for confirmation. ▪ If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-HLA antibodies in both the product and the patient's serum. 5.10 Interference with Laboratory Tests After infusion of IgG, the transitory rise of the various passively transferred antibodies in the patient's blood may yield false positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs') test. Administration of immune globulin products, including GAMMAGARD LIQUID, can lead to false positive readings in assays that depend on detection of beta-D-glucans for diagnosis of fungal infections; this may persist during the weeks following infusion of the product.
warnings and cautions
5.1 Hypersensitivity Severe hypersensitivity reactions may occur, even in patients who had tolerated previous treatment with human normal immune globulin. In case of hypersensitivity, discontinue GAMMAGARD LIQUID infusion immediately and institute appropriate treatment. GAMMAGARD LIQUID contains trace amount of IgA (average concentration of 37 μg/mL). Patients with antibodies to IgA have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. GAMMAGARD LIQUID is contraindicated in patients with antibodies against IgA and a history of hypersensitivity reaction [see Contraindications (4.1) ] .
warnings and cautions
5.2 Renal Dysfunction/Failure Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur upon use of IGIV treatment, especially those containing sucrose 3 . Acute renal dysfunction/failure has been reported in association with infusions of GAMMAGARD LIQUID. Assure that patients are not volume depleted prior to the initiation of infusion of GAMMAGARD LIQUID. In patients who are at risk of developing renal dysfunction because of pre-existing renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs, etc.), administer GAMMAGARD LIQUID intravenously at the minimum rate of infusion practicable (not exceeding 3.3 mg IgG/kg/min (<2 mL/kg/hr) [see Dosage and Administration (2.5) ] . Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk for developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of GAMMAGARD LIQUID and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation of GAMMAGARD LIQUID [see Dosage and Administration (2.5) ] .
warnings and cautions
5.3 Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia Hyperproteinemia, increased serum viscosity and hyponatremia may occur in patients receiving GAMMAGARD LIQUID. It is critical to distinguish true hyponatremia from pseudohyponatremia that is temporally or causally related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap. Treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity, and a predisposition to thromboembolic events. 4
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS Primary Immunodeficiency (PI) Intravenous administration: The serious adverse reaction (AR) seen during intravenous treatment in the clinical studies for PI was aseptic meningitis. The most common adverse reactions for PI (observed in ≥5% of subjects) were headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, oedema peripheral, pruritus, and cardiac murmur. Subcutaneous Administration: No serious adverse reactions were observed during the clinical study of subcutaneous treatment. The most common adverse reactions during subcutaneous treatment (observed in ≥5% of PI subjects) were infusion site (local) event, headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, and pain in extremity. Multifocal Motor Neuropathy (MMN) The serious adverse reactions in the clinical study for MMN were pulmonary embolism and blurred vision. The most common adverse reactions for MMN (observed in ≥5% of subjects) were headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, and pain in extremity. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The most common adverse reactions observed in ≥5% of clinical study subjects receiving GAMMAGARD LIQUID for CIDP were headache, pyrexia, anemia, leukopenia, neutropenia, illness, blood creatinine increased, dizziness, migraine, somnolence, tremor, nasal dryness, abdominal pain upper, vomiting, chills, nasopharyngitis, and pain in extremity. The most common adverse reactions observed in ≥5% of subjects were: PI : Intravenous Administration : Headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, oedema peripheral, pruritus, and cardiac murmur. ( 6.1 ) Subcutaneous Administration : Infusion site (local) event, headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, and pain in extremity. ( 6.1 ) MMN : Headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, and pain in extremity. ( 6.1 ) CIDP: Headache, pyrexia anemia, leukopenia, neutropenia, illness, blood creatinine increased, dizziness, migraine, somnolence, tremor, nasal dryness, abdominal pain upper, vomiting, chills, nasopharyngitis, and pain in extremity. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. Treatment of Primary Immunodeficiency (Intravenous) The safety of GAMMAGARD LIQUID intravenous infusion was evaluated in 61 subjects. Fifteen adverse reactions in 8 subjects were serious. Of these, two episodes of aseptic meningitis in one subject were deemed possibly related to infusion of GAMMAGARD LIQUID. There were 400 non-serious adverse reactions. Of these, 217 were rated as mild (transient discomfort that resolves spontaneously or with minimal intervention), 164 were rated as moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae), and 19 were rated as severe (marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae). All of the severe non-serious adverse experiences were transient, did not lead to hospitalization, and resolved without complication. One subject withdrew from the study due to a non-serious adverse experience (papular rash). Adverse reactions with a frequency of ≥5% (defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period) are shown in Table 8 . Table 8: Adverse Reactions Occurring in ≥5% of Subjects with PI (Intravenous Administration) Events By Infusion N (%) (N=1812 Infusions) By Subject N (%) (N=61 Subjects) Headache 94 (5.2%) 29 (47.5%) Fatigue 33 (1.8%) 14 (23.0%) Pyrexia 28 (1.5%) 17 (27.9%) Nausea 17 (0.9%) 11 (18.0%) Chills 14 (0.8%) 8 (13.1%) Rigors 14 (0.8%) 8 (13.1%) Pain in extremity 13 (0.7%) 7 (11.5%) Diarrhea 12 (0.7%) 9 (14.8%) Migraine 12 (0.7%) 4 (6.6%) Dizziness 11 (0.6%) 8 (13.1%) Vomiting 11 (0.6%) 9 (14.8%) Cough 9 (0.5%) 8 (13.1%) Urticaria 9 (0.5%) 5 (8.2%) Asthma 7 (0.4%) 6 (9.8%) Pharyngolaryngeal pain 7 (0.4%) 5 (8.2%) Rash 6 (0.3%) 4 (6.6%) Arthralgia 5 (0.3%) 4 (6.6%) Myalgia 5 (0.3%) 5 (8.2%) Oedema peripheral 5 (0.3%) 5 (8.2%) Pruritus 5 (0.3%) 4 (6.6%) Cardiac murmur 4 (0.2%) 4 (6.6%) Pooled analysis of 4 short term clinical studies with 106 subjects (total of 854 infusions) showed no differences in the safety profile of GAMMAGARD LIQUID. These short-term studies were designed to stabilize the immune globulin treatment or as a safety follow-up study. They were not designed to study the safety, efficacy and tolerability of GAMMAGARD LIQUID. No additional adverse reactions were reported during the study periods. Treatment of Primary Immunodeficiency (Subcutaneous) The safety of GAMMAGARD LIQUID in subcutaneous infusion was evaluated in 47 subjects. Adverse reactions with a frequency of ≥5% (defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period) are shown in Table 9 . Table 9: Adverse Reactions Occurring in ≥5% of Subjects with PI (Subcutaneous Administration) Events By Infusion N (%) (N=2294 infusions) By Subject N (%) (N=47 Subjects) Infusion site (local) event 55 (2.4%) 21 (44.7%) Headache 31 (1.4%) 19 (40.4%) Fatigue 11 (0.5%) 7 (14.9%) Heart rate increased 11 (0.5%) 3 (6.4%) Pyrexia 11 (0.5%) 9 (19.1%) Abdominal pain upper 9 (0.4%) 5 (10.6%) Nausea 7 (0.3%) 3 (6.4%) Vomiting 7 (0.3%) 5 (10.6%) Asthma 6 (0.3%) 4 (8.5%) Blood pressure systolic increased 6 (0.3%) 3 (6.4%) Diarrhea 5 (0.2%) 3 (6.4%) Ear pain 4 (0.2%) 3 (6.4%) Aphthous stomatitis 3 (0.1%) 3 (6.4%) Migraine 3 (0.1%) 3 (6.4%) Oropharyngeal pain 3 (0.1%) 3 (6.4%) Pain in extremity 3 (0.1%) 3 (6.4%) Of the 348 non-serious adverse reactions, 228 were rated as mild (transient discomfort that resolves spontaneously or with minimal intervention), 112 were rated as moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae), and 8 were rated as severe (marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae). Neither of the severe adverse reactions required hospitalization or resulted in sequelae. Local Adverse Reactions : Local adverse reactions reported as mild (transient discomfort that resolves spontaneously or with minimal intervention) were rash, erythema, edema, hemorrhage, and irritation. Local adverse reactions reported as mild or moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae) were pain, hematoma, pruritus, and swelling. One subject withdrew from the study after 10 treatments with GAMMAGARD LIQUID subcutaneous infusion (2.5 months) due to increased fatigue and malaise. The overall rate of local adverse reactions (excluding infections) during subcutaneous treatment was 2.4% per infusion. In subcutaneous naïve subjects, the incidence of local adverse reactions (N=1757 infusions) was 2.8% (2.2% mild and 0.6% moderate with no severe adverse reactions). In the subjects who were subcutaneous experienced (N=537 infusions), the incidence of local adverse reactions was 1.1% (1.1% mild, and no moderate or severe adverse reactions). After all subcutaneous doses were adjusted, only one subject did not reach the maximum rate allowed in the protocol for one or more infusions, 20 mL/site/hour if weight was below 40 kg and 30/mL/hour for weight 40 kg and greater. Overall, 70% (31 of 44) of subjects opted for the highest rate for all infusions. No subject limited the infusion rate due to an adverse reaction. Median duration of each weekly infusion was 1.2 hours (range: 0.8-2.3 hours). The rate set on the pump was the rate per site multiplied by the number of sites, with no maximum. During subcutaneous treatment, 99.8% of infusions were completed without a reduction, interruption, or discontinuation for tolerability reasons. The proportion of subjects who experienced local adverse reactions (excluding infections) was highest immediately following the switch from intravenous to subcutaneous treatment in all age groups. The rate of local adverse reactions per infusion immediately after switching from intravenous to subcutaneous treatment was 4.9% (29/595), decreasing to 1.5% (8/538) by the end of the study and to 1.1% (10/893) in the Study Extension. There was a decrease of local adverse reactions over subsequent subcutaneous infusions. Eight (17%) subjects experienced a local adverse reaction during the first infusion, but that decreased to 1 (2.2%) for subsequent infusions, ranging from 0 to 4 (8.7%) during the first year of subcutaneous treatment. No subject reported a local adverse reaction from week 53 to end of study at week 68. Analysis of a short-term follow-up safety study of 10 subjects who were treated with subcutaneous administration of GAMMAGARD LIQUID (total of 218 infusions) showed no differences in the safety profile. The follow-up safety study was not designed to study the safety, efficacy and tolerability of GAMMAGARD LIQUID and no additional adverse reactions were reported during the study period. Treatment of Multifocal Motor Neuropathy (Intravenous) The safety of GAMMAGARD LIQUID was evaluated in 44 subjects with MMN who received a total of 983 infusions. Two serious adverse reactions, pulmonary embolism and blurred vision, occurred. In the study, among the 317 non-serious adverse reactions, 176 were considered ARs. Of these, 126 were mild (transient discomfort that resolves spontaneously or with minimal intervention), 37 were moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae) and 13 were severe (marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae). Adverse reactions with a frequency ≥5% (defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period) are shown in Table 10 . Table 10: Adverse Reactions Occurring in ≥5% of MMN Subjects Events GAMMAGARD LIQUID Placebo By Infusion N (%) (N=983 Infusions) By Subject N (%) (N=44 Subjects) By Infusion N (%) (N=129 Infusions) By Subject N (%) (N=43 Subjects) Headache 28 (2.85%) 14 (31.82%) 3 (2.33%) 2 (4.65%) Chest Discomfort 3 (0.31%) 3 (6.82%) 0 (0.00%) 0 (0.00%) Muscle Spasms 3 (0.31%) 3 (6.82%) 0 (0.00%) 0 (0.00%) Muscular weakness 4 (0.41%) 3 (6.82%) 1 (0.78%) 1 (2.33%) Nausea 28 (2.85%) 3 (6.82%) 2 (1.55%) 1 (2.33%) Oropharyngeal pain 4 (0.41%) 3 (6.82%) 0 (0.00%) 0 (0.00%) Pain in extremity 4 (0.41%) 3 (6.82%) 1 (0.78%) 1 (2.33%) Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (Intravenous) The safety of GAMMAGARD LIQUID was evaluated in a clinical study of 20 adult subjects with CIDP. A total of 389 infusions of GAMMAGARD LIQUID were administered during the study. Fourteen out of the 20 subjects reported 60 adverse events; 9 experienced mild events (transient discomfort that resolves spontaneously or with minimal intervention), 3 had moderate events (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae), and 2 experienced severe events (marked impairment of function or can lead to a temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae). There were 39 ARs in 13 subjects (65%), and 31 related to GAMMAGARD LIQUID in 11 subjects (55%). One subject (5%) experienced one severe AR (headache) related to GAMMAGARD LIQUID. No AR resulted in early discontinuation or death, and no serious AR was reported. Adverse reactions with a frequency ≥5% (defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period) are shown in Table 11 . Table 11: Adverse Reactions Occurring in ≥5% of CIDP Subjects Events By Infusion N (%) (N=389 Infusions) By Subject N (%) (N=20 Subjects) Headache 20 (5.1%) 8 (40.0%) Pyrexia 3 (0.8%) 2 (10.0%) Abdominal pain upper 1 (0.3%) 1 (5.0%) Anemia 1 (0.3%) 1 (5.0%) Blood creatinine increased 1 (0.3%) 1 (5.0%) Chills 2 (0.5%) 1 (5.0%) Dizziness 1 (0.3%) 1 (5.0%) Illness 1 (0.3%) 1 (5.0%) Leukopenia 1 (0.3%) 1 (5.0%) Migraine 1 (0.3%) 1 (5.0%) Nasal Dryness 1 (0.3%) 1 (5.0%) Nasopharyngitis 1 (0.3%) 1 (5.0%) Neutropenia 1 (0.3%) 1 (5.0%) Pain in extremity 1 (0.3%) 1 (5.0%) Somnolence 1 (0.3%) 1 (5.0%) Tremor 1 (0.3%) 1 (5.0%) Vomiting 1 (0.3%) 1 (5.0%) 6.2 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. Intravenous Adverse Reactions Blood and Lymphatic System Disorders: Hemolysis Immune System Disorders: Anaphylactic shock Nervous System Disorders: Cerebral vascular accident, transient ischemic attack, tremor Cardiac Disorders: Myocardial infarction Vascular Disorders: Deep vein thrombosis, hypotension Respiratory, Thoracic and Mediastinal Disorders: Pulmonary embolism, pulmonary edema Skin and Subcutaneous Tissue Disorders: Hyperhidrosis General Disorders and Administration-Site Conditions: Chest pain Investigations: Coombs direct test positive, oxygen saturation decreased Injury, Poisoning and Procedural Complications: Transfusion-related acute lung injury Subcutaneous Adverse Reactions Immune System Disorders: Hypersensitive Musculoskeletal and Connective Tissue Disorders: Myalgia General Disorders and Administration-Site Conditions: Chills In addition to the adverse reactions listed above, the following reactions have been identified for immune globulin products administered intravenously: Renal and Urinary Disorders: Osmotic nephropathy Respiratory, Thoracic and Mediastinal Disorders: Cyanosis, hypoxemia, bronchospasm, apnea, Acute Respiratory Distress Syndrome (ARDS) Integumentary : Bullous dermatitis, epidermolysis, erythema multiforme, Stevens-Johnson Syndrome Vascular Disorders: Cardiac arrest, vascular collapse Nervous System Disorders: Coma, seizures, loss of consciousness Blood and Lymphatic System Disorders: Pancytopenia Gastrointestinal: Hepatic dysfunction The adverse reactions listed below have been identified and reported with the use of another immune globulin products administered subcutaneously: Immune System Disorders: Anaphylactic reaction Nervous System Disorders: Paresthesia, tremor Cardiac Disorders: Tachycardia Vascular Disorders: Hypotension Respiratory, Thoracic and Mediastinal Disorders: Dyspnea, laryngospasm General Disorders and Administration-Site Conditions: Chest discomfort, injection site reaction (including induration, warmth)
adverse reactions
6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. Treatment of Primary Immunodeficiency (Intravenous) The safety of GAMMAGARD LIQUID intravenous infusion was evaluated in 61 subjects. Fifteen adverse reactions in 8 subjects were serious. Of these, two episodes of aseptic meningitis in one subject were deemed possibly related to infusion of GAMMAGARD LIQUID. There were 400 non-serious adverse reactions. Of these, 217 were rated as mild (transient discomfort that resolves spontaneously or with minimal intervention), 164 were rated as moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae), and 19 were rated as severe (marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae). All of the severe non-serious adverse experiences were transient, did not lead to hospitalization, and resolved without complication. One subject withdrew from the study due to a non-serious adverse experience (papular rash). Adverse reactions with a frequency of ≥5% (defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period) are shown in Table 8 . Table 8: Adverse Reactions Occurring in ≥5% of Subjects with PI (Intravenous Administration) Events By Infusion N (%) (N=1812 Infusions) By Subject N (%) (N=61 Subjects) Headache 94 (5.2%) 29 (47.5%) Fatigue 33 (1.8%) 14 (23.0%) Pyrexia 28 (1.5%) 17 (27.9%) Nausea 17 (0.9%) 11 (18.0%) Chills 14 (0.8%) 8 (13.1%) Rigors 14 (0.8%) 8 (13.1%) Pain in extremity 13 (0.7%) 7 (11.5%) Diarrhea 12 (0.7%) 9 (14.8%) Migraine 12 (0.7%) 4 (6.6%) Dizziness 11 (0.6%) 8 (13.1%) Vomiting 11 (0.6%) 9 (14.8%) Cough 9 (0.5%) 8 (13.1%) Urticaria 9 (0.5%) 5 (8.2%) Asthma 7 (0.4%) 6 (9.8%) Pharyngolaryngeal pain 7 (0.4%) 5 (8.2%) Rash 6 (0.3%) 4 (6.6%) Arthralgia 5 (0.3%) 4 (6.6%) Myalgia 5 (0.3%) 5 (8.2%) Oedema peripheral 5 (0.3%) 5 (8.2%) Pruritus 5 (0.3%) 4 (6.6%) Cardiac murmur 4 (0.2%) 4 (6.6%) Pooled analysis of 4 short term clinical studies with 106 subjects (total of 854 infusions) showed no differences in the safety profile of GAMMAGARD LIQUID. These short-term studies were designed to stabilize the immune globulin treatment or as a safety follow-up study. They were not designed to study the safety, efficacy and tolerability of GAMMAGARD LIQUID. No additional adverse reactions were reported during the study periods. Treatment of Primary Immunodeficiency (Subcutaneous) The safety of GAMMAGARD LIQUID in subcutaneous infusion was evaluated in 47 subjects. Adverse reactions with a frequency of ≥5% (defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period) are shown in Table 9 . Table 9: Adverse Reactions Occurring in ≥5% of Subjects with PI (Subcutaneous Administration) Events By Infusion N (%) (N=2294 infusions) By Subject N (%) (N=47 Subjects) Infusion site (local) event 55 (2.4%) 21 (44.7%) Headache 31 (1.4%) 19 (40.4%) Fatigue 11 (0.5%) 7 (14.9%) Heart rate increased 11 (0.5%) 3 (6.4%) Pyrexia 11 (0.5%) 9 (19.1%) Abdominal pain upper 9 (0.4%) 5 (10.6%) Nausea 7 (0.3%) 3 (6.4%) Vomiting 7 (0.3%) 5 (10.6%) Asthma 6 (0.3%) 4 (8.5%) Blood pressure systolic increased 6 (0.3%) 3 (6.4%) Diarrhea 5 (0.2%) 3 (6.4%) Ear pain 4 (0.2%) 3 (6.4%) Aphthous stomatitis 3 (0.1%) 3 (6.4%) Migraine 3 (0.1%) 3 (6.4%) Oropharyngeal pain 3 (0.1%) 3 (6.4%) Pain in extremity 3 (0.1%) 3 (6.4%) Of the 348 non-serious adverse reactions, 228 were rated as mild (transient discomfort that resolves spontaneously or with minimal intervention), 112 were rated as moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae), and 8 were rated as severe (marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae). Neither of the severe adverse reactions required hospitalization or resulted in sequelae. Local Adverse Reactions : Local adverse reactions reported as mild (transient discomfort that resolves spontaneously or with minimal intervention) were rash, erythema, edema, hemorrhage, and irritation. Local adverse reactions reported as mild or moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae) were pain, hematoma, pruritus, and swelling. One subject withdrew from the study after 10 treatments with GAMMAGARD LIQUID subcutaneous infusion (2.5 months) due to increased fatigue and malaise. The overall rate of local adverse reactions (excluding infections) during subcutaneous treatment was 2.4% per infusion. In subcutaneous naïve subjects, the incidence of local adverse reactions (N=1757 infusions) was 2.8% (2.2% mild and 0.6% moderate with no severe adverse reactions). In the subjects who were subcutaneous experienced (N=537 infusions), the incidence of local adverse reactions was 1.1% (1.1% mild, and no moderate or severe adverse reactions). After all subcutaneous doses were adjusted, only one subject did not reach the maximum rate allowed in the protocol for one or more infusions, 20 mL/site/hour if weight was below 40 kg and 30/mL/hour for weight 40 kg and greater. Overall, 70% (31 of 44) of subjects opted for the highest rate for all infusions. No subject limited the infusion rate due to an adverse reaction. Median duration of each weekly infusion was 1.2 hours (range: 0.8-2.3 hours). The rate set on the pump was the rate per site multiplied by the number of sites, with no maximum. During subcutaneous treatment, 99.8% of infusions were completed without a reduction, interruption, or discontinuation for tolerability reasons. The proportion of subjects who experienced local adverse reactions (excluding infections) was highest immediately following the switch from intravenous to subcutaneous treatment in all age groups. The rate of local adverse reactions per infusion immediately after switching from intravenous to subcutaneous treatment was 4.9% (29/595), decreasing to 1.5% (8/538) by the end of the study and to 1.1% (10/893) in the Study Extension. There was a decrease of local adverse reactions over subsequent subcutaneous infusions. Eight (17%) subjects experienced a local adverse reaction during the first infusion, but that decreased to 1 (2.2%) for subsequent infusions, ranging from 0 to 4 (8.7%) during the first year of subcutaneous treatment. No subject reported a local adverse reaction from week 53 to end of study at week 68. Analysis of a short-term follow-up safety study of 10 subjects who were treated with subcutaneous administration of GAMMAGARD LIQUID (total of 218 infusions) showed no differences in the safety profile. The follow-up safety study was not designed to study the safety, efficacy and tolerability of GAMMAGARD LIQUID and no additional adverse reactions were reported during the study period. Treatment of Multifocal Motor Neuropathy (Intravenous) The safety of GAMMAGARD LIQUID was evaluated in 44 subjects with MMN who received a total of 983 infusions. Two serious adverse reactions, pulmonary embolism and blurred vision, occurred. In the study, among the 317 non-serious adverse reactions, 176 were considered ARs. Of these, 126 were mild (transient discomfort that resolves spontaneously or with minimal intervention), 37 were moderate (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae) and 13 were severe (marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae). Adverse reactions with a frequency ≥5% (defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period) are shown in Table 10 . Table 10: Adverse Reactions Occurring in ≥5% of MMN Subjects Events GAMMAGARD LIQUID Placebo By Infusion N (%) (N=983 Infusions) By Subject N (%) (N=44 Subjects) By Infusion N (%) (N=129 Infusions) By Subject N (%) (N=43 Subjects) Headache 28 (2.85%) 14 (31.82%) 3 (2.33%) 2 (4.65%) Chest Discomfort 3 (0.31%) 3 (6.82%) 0 (0.00%) 0 (0.00%) Muscle Spasms 3 (0.31%) 3 (6.82%) 0 (0.00%) 0 (0.00%) Muscular weakness 4 (0.41%) 3 (6.82%) 1 (0.78%) 1 (2.33%) Nausea 28 (2.85%) 3 (6.82%) 2 (1.55%) 1 (2.33%) Oropharyngeal pain 4 (0.41%) 3 (6.82%) 0 (0.00%) 0 (0.00%) Pain in extremity 4 (0.41%) 3 (6.82%) 1 (0.78%) 1 (2.33%) Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (Intravenous) The safety of GAMMAGARD LIQUID was evaluated in a clinical study of 20 adult subjects with CIDP. A total of 389 infusions of GAMMAGARD LIQUID were administered during the study. Fourteen out of the 20 subjects reported 60 adverse events; 9 experienced mild events (transient discomfort that resolves spontaneously or with minimal intervention), 3 had moderate events (limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae), and 2 experienced severe events (marked impairment of function or can lead to a temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae). There were 39 ARs in 13 subjects (65%), and 31 related to GAMMAGARD LIQUID in 11 subjects (55%). One subject (5%) experienced one severe AR (headache) related to GAMMAGARD LIQUID. No AR resulted in early discontinuation or death, and no serious AR was reported. Adverse reactions with a frequency ≥5% (defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period) are shown in Table 11 . Table 11: Adverse Reactions Occurring in ≥5% of CIDP Subjects Events By Infusion N (%) (N=389 Infusions) By Subject N (%) (N=20 Subjects) Headache 20 (5.1%) 8 (40.0%) Pyrexia 3 (0.8%) 2 (10.0%) Abdominal pain upper 1 (0.3%) 1 (5.0%) Anemia 1 (0.3%) 1 (5.0%) Blood creatinine increased 1 (0.3%) 1 (5.0%) Chills 2 (0.5%) 1 (5.0%) Dizziness 1 (0.3%) 1 (5.0%) Illness 1 (0.3%) 1 (5.0%) Leukopenia 1 (0.3%) 1 (5.0%) Migraine 1 (0.3%) 1 (5.0%) Nasal Dryness 1 (0.3%) 1 (5.0%) Nasopharyngitis 1 (0.3%) 1 (5.0%) Neutropenia 1 (0.3%) 1 (5.0%) Pain in extremity 1 (0.3%) 1 (5.0%) Somnolence 1 (0.3%) 1 (5.0%) Tremor 1 (0.3%) 1 (5.0%) Vomiting 1 (0.3%) 1 (5.0%)
adverse reactions
6.2 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. Intravenous Adverse Reactions Blood and Lymphatic System Disorders: Hemolysis Immune System Disorders: Anaphylactic shock Nervous System Disorders: Cerebral vascular accident, transient ischemic attack, tremor Cardiac Disorders: Myocardial infarction Vascular Disorders: Deep vein thrombosis, hypotension Respiratory, Thoracic and Mediastinal Disorders: Pulmonary embolism, pulmonary edema Skin and Subcutaneous Tissue Disorders: Hyperhidrosis General Disorders and Administration-Site Conditions: Chest pain Investigations: Coombs direct test positive, oxygen saturation decreased Injury, Poisoning and Procedural Complications: Transfusion-related acute lung injury Subcutaneous Adverse Reactions Immune System Disorders: Hypersensitive Musculoskeletal and Connective Tissue Disorders: Myalgia General Disorders and Administration-Site Conditions: Chills In addition to the adverse reactions listed above, the following reactions have been identified for immune globulin products administered intravenously: Renal and Urinary Disorders: Osmotic nephropathy Respiratory, Thoracic and Mediastinal Disorders: Cyanosis, hypoxemia, bronchospasm, apnea, Acute Respiratory Distress Syndrome (ARDS) Integumentary : Bullous dermatitis, epidermolysis, erythema multiforme, Stevens-Johnson Syndrome Vascular Disorders: Cardiac arrest, vascular collapse Nervous System Disorders: Coma, seizures, loss of consciousness Blood and Lymphatic System Disorders: Pancytopenia Gastrointestinal: Hepatic dysfunction The adverse reactions listed below have been identified and reported with the use of another immune globulin products administered subcutaneously: Immune System Disorders: Anaphylactic reaction Nervous System Disorders: Paresthesia, tremor Cardiac Disorders: Tachycardia Vascular Disorders: Hypotension Respiratory, Thoracic and Mediastinal Disorders: Dyspnea, laryngospasm General Disorders and Administration-Site Conditions: Chest discomfort, injection site reaction (including induration, warmth)
adverse reactions table
<table ID="_Ref464557252" width="100%"><caption>Table 8: Adverse Reactions Occurring in ≥5% of Subjects with PI (Intravenous Administration)</caption><col width="30%"/><col width="30%"/><col width="40%"/><tbody><tr styleCode="Toprule"><td styleCode="Lrule Rrule Toprule Botrule" valign="middle"><paragraph><content styleCode="bold">Events</content></paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph><content styleCode="bold">By Infusion N (%)</content></paragraph><paragraph><content styleCode="bold">(N=1812 Infusions)</content></paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph><content styleCode="bold">By Subject N (%)</content></paragraph><paragraph><content styleCode="bold">(N=61 Subjects)</content></paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Headache</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>94 (5.2%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>29 (47.5%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Fatigue</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>33 (1.8%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>14 (23.0%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Pyrexia</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>28 (1.5%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>17 (27.9%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Nausea</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>17 (0.9%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>11 (18.0%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Chills</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>14 (0.8%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>8 (13.1%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Rigors</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>14 (0.8%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>8 (13.1%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Pain in extremity</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>13 (0.7%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>7 (11.5%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Diarrhea</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>12 (0.7%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>9 (14.8%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Migraine</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>12 (0.7%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>4 (6.6%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Dizziness</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>11 (0.6%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>8 (13.1%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Vomiting</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>11 (0.6%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>9 (14.8%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Cough</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>9 (0.5%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>8 (13.1%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Urticaria</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>9 (0.5%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>5 (8.2%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Asthma</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>7 (0.4%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>6 (9.8%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Pharyngolaryngeal pain</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>7 (0.4%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>5 (8.2%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Rash</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>6 (0.3%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>4 (6.6%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Arthralgia</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>5 (0.3%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>4 (6.6%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Myalgia</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>5 (0.3%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>5 (8.2%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Oedema peripheral</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>5 (0.3%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>5 (8.2%)</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Pruritus</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>5 (0.3%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>4 (6.6%)</paragraph></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Cardiac murmur</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>4 (0.2%)</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>4 (6.6%)</paragraph></td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.